Active Health
NuCapCure

Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis

€5.9MFunding
54Months
7Partners

Fact sheet

Programme
Horizon Europe & sub-programmes
Companies
EURICE
Duration
54 months (February 2024 – July 2028)
Project funding
€ 5,972,875.75
Project partners
7
Technology readiness level
1-3
Project website
https://www.nucapcure.eu/

Project contact(s)

About the project

Glioblastoma multiforme (GBM) is one of the most common types of brain cancer. Of the approximately 240,000 people a year who are diagnosed with brain cancer, GBM accounts for 14.6-16% of them. The current treatment options, which involve surgery followed by a combination of chemotherapy and radiotherapy, have a limited curative impact and impose a significant health and financial burden on patients and the healthcare system.

Therefore, the research project NuCapCure aims to create an innovative treatment strategy by creating customised boron-containing photosensitisers (PSs) using intracellular biochemistry. The project combines proton radiotherapy, proton-induced PS activation, boron neutron capture therapy (BNCT), and neutron-induced PS activation. One of the core objectives of the NuCapCure project focuses on the design, development, validation, and optimisation of boron-modified PS prodrugs. These compounds will facilitate the intracellular production of boron-modified PSs by hijacking vital biosynthetic pathways. Put differently, the cancer cells will become small individual chemical laboratories that generate the final drugs, leading to their destruction through neutron- or accelerated proton-based treatments. The specificity of the bespoke PSs to the cancer cells is crucial for sparing the normal tissue surrounding the lesions.

Coordinator

Theodossis Theodossiou
University of Oslo
Email coordinator